Hims & Hers' (NYSE: HIMS) stock crashed over 30% following news highlighting the end of its relationship with Novo Nordisk ...

If you discover a neighbor's dog trespassing in your garden, and you don't want them to, the first recommendation is to ...

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

Hims & Hers rebounded by 11.76 percent on Thursday to close at $46.28 apiece amid reaffirmations to continue offering cheaper ...

This growth stock experienced a significant decline in stock price following an announcement with a key partner. *Stock prices used were the afternoon prices of June 23, 2025. The video was published ...

Eight-time Grand Slam winner André Agassi has spoken of the deep “trust” he shares with wife Steffi Graf, a fellow tennis ...

Novo Nordisk has bounced back from a sour ending to its Hims & Hers partnership, revealing a new deal with WeightWatchers to ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

Labrum is the founder of Meg Matters, a young nonprofit dedicated to suicide prevention and sharing mental health resources ...

No matter how much you love these speculative winners, you don’t have a gain until you actually ring the register.

Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.

Novo Nordisk is expanding access to its drug Wegovy through a new partnership with WeightWatchers, days after cutting ties with telehealth firm Hims & Hers. Starting July 1, WeightWatchers will ...